Table 2. Data Sharing for (Reporting Period)

Request Type \ Funding source	Federal	Non-federal	Industry	Total
Data Only (including APOE and Imaging)				
Tissue (including DNA, CSF, fibroblasts, and brain)				
Participant Requests				
Total				

Table 3. ADC Productivity During (Reporting Period)

- XX center-supported publications
- YY studies supported with data, tissue or participants
- ZZ trainees on K awards or other training grants
- XYZ continuing multi-site collaborations (NACC, NCRAD, ADCS, ATRI, ADNI, LOAD, ADGC, GAP, IDEAS)
- Other collaborations
- Externally funded grant awards

Table 4. ADC Pilot Grant Program for (Reporting Period)

- XX applications from YY departments: Genetics, Neurology, Psychiatry, Biomedical Engineering, etc
- List each Pilot Grant #, name/degree/department of awardee, and Pilot Grant title for each application selected for funding by the ADC's Executive Committee
  - Indicate if any Pilots are being funded with resources other than the ADC budget

Table 5a. ADC Active Cohort (N = XXX)

	CDR 0 N=	**CDR 0.5** N=	**CDR 1** N=
Age (y)			
Education (y)			
Male (%)			
African American (%)			
MMSE			
% with *APOE4* allele			

Note: Other variables may be incorporated; for example, some ADCs may wish to replace the MMSE with the MoCA. Also, the summary statistics may include the clinical diagnoses of individuals who are cognitively impaired (see Table 5b).

Table 5b. ADC Active Cohort (N = XXX)

Disorder/Syndrome (D1)	N=
MCI	
Amnestic dementia	
PCA	
PPA	
bvFTD	
DLB	
Nonamnestic multidomain	
Other	

Etiology (D1)	N=
AD	
LBD	
MSA	
PSP	
CBD	
FTLD-MND	
FTLD-NOS	
Vascular	

Note: Data can be pulled from NACC Form D1

Table 6. Autopsy Rate (Reporting Period)

- ADC Participants (everyone with one or more ADC clinical assessment)
  - XX autopsies in YY deaths; XX/YY = ZZ%

Table 7. ADC Participation in Study Procedures

(ever in active participants)

	2015	2016	2017
Amyloid PET imaging			
CSF			
MRI			
Blood for Genetics			

Note: If other biomarkers variables are obtained by the ADC, they also should be included (eg, tau PET imaging; fibroblast collection for generation of induced pluripotent stem cells, etc).